Composition and method for the treatment of dysglucaemia

US6815433B2 · kind B2 · utility

Assignee

• Metcon Medicin AB · SE

Inventors

• Henri Hansson · Helsingborg, SE
• Mats Lake · Lidingö, SE
• Kerstin Hansson · Lund, SE

Key dates

• Filing date: Oct 25, 2001
• Grant date: Nov 9, 2004
• Expiry date: Oct 25, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P3/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Dysglucaemia is treated and/or prevented by the administration of granulated starch, enzymatically degraded and releasing reducing sugars at a rate, adjusted to the metabolism of the patient, suffering from dysglucaemia. For example nocturnal hypoglycaemia in diabetic patients is prevented by administering to said patients a granulate or tablets comprising granulated cornstarch, and preferably also heat treated cornstarch and a low calorie sweetener. The inventive granulation minimizes the available surface area and retards the enzymatic degradation of the cornstarch and ensures a controlled, e.g. a substantially linear release of reducing sugars, such as glucose, and a stable blood glucose level during several hours. The granulate or tablets are low in calories and contain no free sugar.